Sidney Pitt
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Synthesis and biological activity, Computational Drug Discovery Methods, Cytokine Signaling Pathways and Interactions, Synthesis and Characterization of Heterocyclic Compounds
Most-Cited Works
- → Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays(2004)1,285 cited
- → 2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure−Activity Relationship Studies toward the Discovery of N -(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent pan -Src Kinase Inhibitor(2006)395 cited
- → Discovery of 2-amino-heteroaryl-benzothiazole-6-anilides as potent p56lck inhibitors(2003)106 cited
- → Design, Synthesis, and Anti-inflammatory Properties of Orally Active 4-(Phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38α Mitogen-Activated Protein Kinase Inhibitors(2007)81 cited
- → 5-Cyanopyrimidine Derivatives as a Novel Class of Potent, Selective, and Orally Active Inhibitors of p38α MAP Kinase(2005)70 cited
- → Molecular design, synthesis, and structure–Activity relationships leading to the potent and selective p56lck inhibitor BMS-243117(2003)58 cited
- → Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56Lck(2003)57 cited
- → Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a Clinical p38α MAP Kinase Inhibitor for the Treatment of Inflammatory Diseases(2010)57 cited
- → Benzothiazole based inhibitors of p38α MAP kinase(2008)51 cited
- → The Discovery of Orally Active Triaminotriazine Aniline Amides as Inhibitors of p38 MAP Kinase(2004)50 cited